Antiviral Drugs Have No Effect on Mortality in COVID-19
FRIDAY, Dec. 4, 2020 -- For hospitalized patients with COVID-19, remdesivir, hydroxychloroquine, lopinavir, and interferon regimens seem to have little to no effect on mortality, according to a study published online Dec. 2 in the New England... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 4, 2020 Category: Pharmaceuticals Source Type: news

Analysis finds four repurposed antiviral drugs have little or no effect on patients hospitalised for COVID-19
Repurposed antiviral drugs - remdesivir, hydroxychloroquine, lopinavir and interferon - to treat COVID-19 appear to have little or no effect on patients hospitalised for the disease, in terms of overall mortality, initiation of ventilation and duration of hospital stay. The interim findings from the WHO Solidarity trial, published in the New England Journal of Medicine (NEJM), followed 11,266 adults at 405 hospitals in 30 countries. (Source: University of Bristol news)
Source: University of Bristol news - December 4, 2020 Category: Universities & Medical Training Tags: Research, International, Health; Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School; Press Release Source Type: news

Systemic Lupus Erythematosus Abstracts From ACR Convergence Systemic Lupus Erythematosus Abstracts From ACR Convergence
Dr Michele Petri highlights abstracts on systemic lupus erythematosus from ACR 2020, including the effects of hydroxychloroquine on QTc length and use of belimumab and obinutuzumab on renal outcomes.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 1, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

US Presidential Election Part 3: President Trump ’s Legacy of Mismanagement of the Pandemic
Credit: Whitehouse.GovBy Farhang JahanpourOXFORD, Dec 1 2020 (IPS) Covid-19 is on track to be the deadliest and one of the most catastrophic epidemics since the 1918-1919 flu pandemic, which infected about 500 million people or one-third of the world’s population at the time. The number of deaths was estimated somewhere between 17 and 50 million, and possibly as high as 100 million worldwide. The first observations of illness and mortality were documented in December 1917 at Camp Greene, North Carolina. To maintain morale, World War I censors minimized reports of casualties, but as newspapers in neutral Spain were free ...
Source: IPS Inter Press Service - Health - December 1, 2020 Category: International Medicine & Public Health Authors: Farhang Jahanpour Tags: Democracy Global Geopolitics Headlines Health North America TerraViva United Nations Source Type: news

Update to information on psychiatric disorders for chloroquine and hydroxychloroquine, EMA
EMA ' s safety committee (PRAC) has recommended updating product information for all chloroquine or hydroxychloroquine-containing medicines following a review that confirmed a link between the use of these medicines and the risk of psychiatric disorders and suicidal behaviour. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 30, 2020 Category: Consumer Health News Source Type: news

Mechanism of action of chloroquine/hydroxychloroquine for COVID-19 infection
(Bentham Science Publishers) The recent serious outbreak of Covid19 has required urgent medical treatments for numerous patients. No clinically active vaccines or antiviral agents are available for Covid19. According to several studies, Chloroquine (CQ) and Hydroxychloroquine (HCQ) have shown promises as Covid19 antiviral especially when administered with Azithromycin (AZM). (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 30, 2020 Category: Infectious Diseases Source Type: news

Rutgers leading coronavirus therapeutic clinical trial
(Rutgers University) Rutgers is leading a clinical trial assessing the combination of nitazoxanide, ribavirin and hydroxychloroquine to treat people 21 or older who are infected with SARS-CoV-2 and are asymptomatic or mildly symptomatic. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 30, 2020 Category: Infectious Diseases Source Type: news

COVID-19: A data challenge and a catalyst for new insights
  One of the key issues that arose during the pandemic, and arguably a factor that has led to more deaths, has been one of healthcare systems, public health and governments having insufficient or no relevant data on which to base critical decisions. The right data are not in the right place to answer the right questions at the right time. Yet, in the midst of this we have also seen remarkable collaboration on the scientific response to the pandemic, from diagnostics to therapeutic and vaccine research and development. We have learned a lot about the virus since its genome was shared by Chinese researchers in January.  ...
Source: EyeForPharma - November 24, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Hydroxychloroquine doesn ’t benefit hospitalized COVID-19 patients
In a final analysis of study data, researchers concluded that the medication hydroxychloroquine provides no benefit to adults hospitalized with COVID-19. (Source: NIH Research Matters)
Source: NIH Research Matters - November 23, 2020 Category: Research Source Type: news

New insight into the effect of hydroxychloroquine undermines its use in COVID-19
(Radboud University Medical Center) Researchers at Radboud university medical center have discovered an as yet unknown effect of hydroxychloroquine. It inhibits the action of a type of white blood cells important in the first line of defense against infections. Based on this research, hydroxychloroquine is unlikely to be beneficial in clearing viral infections including the new coronavirus SARS-CoV-2, they write in their publication inCell Reports Medicine. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 23, 2020 Category: Infectious Diseases Source Type: news

Methotrexate and HCQ Split on Cardiovascular Outcomes in RA Methotrexate and HCQ Split on Cardiovascular Outcomes in RA
No significant differences in major adverse cardiovascular events emerged between methotrexate and hydroxychloroquine treatment in a comparison of adults 65 years or older with rheumatoid arthritis.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 13, 2020 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news

Hydroxychloroquine does not help patients hospitalized with COVID-19: Study
(Vanderbilt University Medical Center) Findings from a national study published today in the Journal of the American Medical Association (JAMA) " do not support " the use of hydroxychloroquine for the treatment of adult patients hospitalized with COVID-19. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 13, 2020 Category: Infectious Diseases Source Type: news

Coronavirus live news: quarter of deaths in France linked to Covid as US tops 140,000 daily cases
France ’s lockdown extended by two weeks; German infection surge may be easing; Russia says its Sputnik-V vaccine is 92% effectiveScientist behind BioNTech/Pfizer vaccine says it can end pandemicBillionaire Trump donors contract Covid after playing down risksCovid infections in Sweden surge, dashing hopes of herd immunityFrench professor faces disciplinary case over hydroxychloroquine claims1.04amGMTOne of the first cruise ships to ply throughCaribbean waters since the pandemic began ended its trip early after five passengers tested positive for Covid-19.The SeaDream is carrying 53 passengers and 66 crew, with the majori...
Source: Guardian Unlimited Science - November 13, 2020 Category: Science Authors: Helen Sullivan Tags: Coronavirus World news Europe UK news US news Science Infectious diseases Source Type: news

French professor faces disciplinary case over hydroxychloroquine claims
Didier Raoult stands accused of touting drug as a coronavirus treatment without evidence (Source: Reuters: Health)
Source: Reuters: Health - November 12, 2020 Category: Consumer Health News Source Type: news

NHLBI Trial Concludes No Benefit for Hydroxychloroquine in COVID-19
THURSDAY, Nov. 12, 2020 -- Hydroxychloroquine is not beneficial for adults hospitalized with COVID-19, according to the formal conclusion of a study funded by the U.S. National Heart, Lung, and Blood Institute (NHLBI) and published online Nov. 9 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 12, 2020 Category: Pharmaceuticals Source Type: news